IDORSIA AG SF-,05 WKN A2DTEB | ISIN CH0363463438 | Aktie Watchlist Musterdepot Alert Factsheet - RT Bid: - | Ask: - - EUR - (-) gettex SIX Swiss Exchange Nasdaq Other OTC Baader Bank (Baadex) Lang & Schwarz Berlin EUREX gettex Hamburg München Verkaufen Kaufen Übersicht Chart-Pro Analysen Nachrichten Kurse & Handelsplätze Letzte Umsätze 06.05.24 GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds 01.05.24 GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond 26.04.24 GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension 23.04.24 GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting 17.04.24 GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting 11.04.24 GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs 22.03.24 GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires 20.03.24 GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives 18.03.24 GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration 28.02.24 GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration 28.02.24 Idorsia and Viatris enter into a significant global research and development collaboration 10.01.24 GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation 03.11.23 GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 03.11.23 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 24.10.23 GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert